Governance in the Age of AI with Author & Investor Eric Ries on June 11 – San Francisco

Helex

Genomic medicines for kidney diseases with high unmet need

Company details

Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure™ 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.

It costs $2 billion to develop a new gene-editing therapy, and $2 million simply to treat one patient.

Helex Quote Image
Poulami Chuadhuri, Ph.D., CEO
We call ourselves the GPS for gene editing, because we really decide on that exact location where the guide RNA can make the cut for a safer therapy, a more efficient therapy, so that there are no more unintended cuts anywhere else in the genome.

Get In Touch with Helex

Please tell us a little bit about yourself and why you'd like to get connected. Helex + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.